Press release article from our research archive:

Herceptin(R) Approved in Europe for use in Combination With an Aromatase Inhibitor for the Treatment of Patients With HER2 and Hormone Receptor-Co-Positive Metastatic Breast Cancer.

BASEL, Switzerland, May 3 /PRNewswire/ --

- The First Combination of Targeted Therapies to Receive Approval for Breast Cancer

Roche announced today that the European Commission has approved the use of Herceptin(R) (trastuzumab) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer.

The approval is based on data from the international phase III TAnDEM study which showed that the addition of Herceptin to hormonal therapy doubled the median progression-free survival (time patients live without their cancer progressing), from 2.4 months to 4.8 months(i).

"Today's ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!